Fulgent Genetics, Inc. (FLGT) CFO has 2,747 shares withheld for taxes

Rhea-AI Filing Summary

Fulgent Genetics, Inc. reports that CFO and Treasurer Paul Kim had 2,747 shares of common stock withheld on July 26, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a 2022 merger. After this tax withholding disposition, he directly owns 359,798 shares.

Insider Trade Summary

Net Seller: 2,747 shares

Net Sell 1 txn

Insider Kim Paul

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	2,747	$19.67	$54K

Holdings After Transaction: Common Stock — 359,798 shares (Direct)

Footnotes (1)

1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

Key Figures

Shares withheld for taxes: 2,747 shares Price per share: $19.67 Shares owned after transaction: 359,798 shares +1 more

4 metrics

Shares withheld for taxes 2,747 shares Common stock withheld on July 26, 2026 to satisfy tax withholding obligations

Price per share $19.67 Value used for the tax-withholding disposition of 2,747 shares

Shares owned after transaction 359,798 shares Direct common stock holdings of Paul Kim following the tax-withholding disposition

Transaction date July 26, 2026 Date of the tax-withholding disposition reported by Paul Kim

Key Terms

restricted stock units, Agreement and Plan of Merger, tax withholding obligations

3 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units assumed"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Agreement and Plan of Merger regulatory

"units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

tax withholding obligations financial

"shares were withheld from the reporting person to satisfy the tax withholding obligations that arose"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:32 PM Accepted by SEC EDGAR 07/28/2026 - 04:32 PM Learn about SEC filing dates

FAQ

What insider transaction did Fulgent Genetics (FLGT) CFO Paul Kim report?

Paul Kim reported a tax-withholding disposition of 2,747 shares of Fulgent Genetics common stock. The shares were withheld to cover taxes triggered by the vesting of restricted stock units that were assumed in a prior merger transaction.

Did Fulgent Genetics (FLGT) CFO Paul Kim sell shares on the open market?

No, the reported transaction was a withholding of 2,747 shares to satisfy tax obligations, not an open-market sale. The shares were retained by the company to cover taxes from the vesting of previously granted restricted stock units.

How many Fulgent Genetics (FLGT) shares does CFO Paul Kim own after this transaction?

Following the tax-withholding disposition, Paul Kim directly owns 359,798 shares of Fulgent Genetics common stock. This figure reflects his direct holdings after 2,747 shares were withheld to cover tax obligations tied to restricted stock unit vesting.

What caused the tax withholding on Fulgent Genetics (FLGT) shares for CFO Paul Kim?

The tax withholding arose from the vesting of restricted stock units that were assumed under a 2022 Agreement and Plan of Merger. When those RSUs vested, 2,747 shares were withheld to satisfy the related tax withholding obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/26/2026		F		2,747(1)	D	$19.67	359,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)